Loading stock data…
NTLA
$13.26-0.22 (-1.63%)
Market ClosedLast close May 1
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Intellia Therapeutics, Inc. in the Healthcare sector is trading at $13.26. The stock is currently 53% below its 52-week high of $28.25, remaining 0.8% above its 200-day moving average. Technical signals show neutral RSI of 45 and bearish MACD signal, explaining why NTLA maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 45) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$13.26
Potential Upside
5%
Whystock Fair Value$13.92
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus20 analysts
Buy
Mean target$26.80+102.1%
Range$5.00 – $95.00
Fundamentals
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyre...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.94B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.99
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-71.52%
Volume
Today's trading volume
5.80M
Recent News
Intellia Therapeutics (NTLA) Is Down 15.1% After Phase 3 lonvo-z Data And $180M Equity Raise - Has The Bull Case Changed?
In late April 2026, Intellia Therapeutics completed a US$180.00 million follow-on offering of 16,744,187 common shares at US$10.75 each, shortly after reporting that its in vivo CRISPR therapy lonvo-z achieved positive Phase 3 HAELO trial results and initiating a rolling BLA submission to the FDA for hereditary angioedema. The combination of first-in-class Phase 3 data for an in vivo CRISPR treatment and an upsized equity raise underscores how Intellia is simultaneously advancing lonvo-z...
Cathie Wood Buys Tumbling Robinhood Stock, ARK Adds $30 Mil Of This Stock
Cathie Wood's ARK Invest bought Robinhood stock as shares fell, loads up on Kratos Defense, Intellia Therapeutics. Firm sells bitcoin ETF.
KalVista Scores $1.9 Billion Takeover Deal; Why A Key Rival Jumped Too
Shares of KalVista Pharmaceuticals catapulted Wednesday on a $1.9 billion takeover offer from Italy's Chiesi Group.
Cathie Wood Loads Up $14 Million on Alphabet Just Before Earnings
Cathie Wood Ramps Up Alphabet Stake Hours Before Key Earnings
NTLA Falls 4% Despite Strong Phase III HAE Data, Initiates Rolling BLA
Intellia shares drop 4% despite phase III data meeting all endpoints. The company begins a rolling FDA filing.